How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

365 results for

Intraocular Carbonic Anhydrase Inhibitor

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. 24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol

Hypertension Eye Diseases Timolol Brimonidine Tartrate Travoprost Brinzolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) 24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol 24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2009 Clinical Trials

82. Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions

: Myocilin gene Glaucoma dorzolamide and timolol combination eyedrop Additional relevant MeSH terms: Layout table for MeSH terms Glaucoma Ocular Hypertension Eye Diseases Timolol Dorzolamide Ophthalmic Solutions Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Pharmaceutical Solutions Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2009 Clinical Trials

83. Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma

: Layout table for MeSH terms Glaucoma Ocular Hypertension Eye Diseases Timolol Brimonidine Tartrate Dorzolamide Brinzolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2009 Clinical Trials

84. Brinzolamide and timolol maleate suspension - Glaucoma and Ocular hypertension

in a similar manner to other carbonic anhydrase inhibitor/beta blocker combination products. Reasons for the Recommendation: 1. In the Common Drug Review (CDR) systematic review that included two double-blind randomized controlled trials, the reduction in intraocular pressure at six months was greater for Azarga compared with either individual component given alone, and was similar for Azarga compared with the combination product of dorzolamide 2% / timolol 0.5% (Cosopt). 2. Azarga costs less than either (...) individual component given alone and costs less than Cosopt. Of Note: The Committee noted that while Azarga costs less than other carbonic anhydrase inhibitor/beta blocker ophthalmic combination products, it costs more than prostaglandin analogue/beta blocker combination products. Background: Azarga is a combination of timolol, a beta-blocker, and brinzolamide, a carbonic anhydrase inhibitor. It has a Health Canada indication for the reduction of intraocular pressure (IOP) in patients with open-angle

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

85. Simbrinza - brinzolamide / brimonidine tartrate

2.3.1. Pharmacology Primary pharmacodynamic studies Brinzolamide is a potent and selective inhibitor of carbonic anhydrase-II. Following topical ocular administration, brinzolamide inhibited aqueous humour formation and reduced elevated intraocular pressure (IOP). The topical ocular application of brinzolamide was shown to dose- dependently reduce IOP by up to 30% in ocular hypertensive monkeys and pigmented rabbits. Brimonidine tartrate is a potent, selective alpha-2 adrenoceptor agonist (...) mg/mL Eye Drops, Suspension cAMP Cyclic AMP CA Carbonic anhydrase CAI Carbonic anhydrase inhibitor CHMP Committee for Medicinal Products for human Use CI Confidence interval CNS Central nervous system CYP3A4 Cytochrome P450 3A4 a member of the cytochrome P45 mixed-function oxidase system EFD Embryo-foetal development eg Exempli gratia (for the sake of an example) EMA European Medicines Agency EU European Union FDA Food and Drug Administration g Gram GTP Guanosine triphosphate H or h Hour i.e. id

2014 European Medicines Agency - EPARs

86. Dorzolamide-timolol Drops With Injections to Treat AMD,RVO or DME.

Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Growth Substances Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Study Start Date : October 1, 2014 Actual Primary Completion Date : July 10, 2017 Actual Study Completion Date : December 1, 2017 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Dorzolamide-timolol On enrollment, eligible patients will have visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan and will then receive the same intravitreal

2015 Clinical Trials

87. Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle Closure

worse visual acuity will be selected. Only one eye per patient is eligible for the study. Drug washout: Eligible patients who are already on anti-glaucoma medications are required to have drug washout before being randomized. Various medications have different washout periods: Prostaglandin analogues 4 weeks, Beta blockers 3 weeks, Adrenergic agonist 2 weeks, Cholinergic agonist 5 days, Carbonic Anhydrase Inhibitors 5 days. Patients whose IOP>30 mm Hg during this washout period will be stopped from (...) after LPIP procedure. Drug: Proparacaine 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered Outcome Measures Go to Primary Outcome Measures : Progression rate determined by number of patients who progress after laser treatment for each group. [ Time Frame: 3 years ] PAC progression defined as presence of any of the following: Acute angle closure crisis Intraocular (IOP) was 8mmHg higher

2015 Clinical Trials

88. Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

of oral prednisone at baseline (M01 study visit) dose stability requirement for past 4 weeks does not apply); Systemic immunosuppressive drug therapy that has not been stable for at least 4 weeks (note: use of systemic methotrexate is acceptable as long as regimen has been stable for at least 4 weeks); Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline; Known allergy or hypersensitivity to any component of the study drugs; For women of childbearing potential (...) variable with a limited duration. Persistent macular edema is a common occurrence and often requires repeated intravitreal injections of corticosteroids, which expose eyes to a significant risk of increased intraocular pressure ocular and cataract development. The often refractory nature of uveitic ME and its impact on visual function underscores the need to identify effective alternative medical therapeutic options. Recent pilot studies have shown intravitreal methotrexate (MTX) and intravitreal

2015 Clinical Trials

89. SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

Tartrate Latanoprost Brinzolamide Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Information provided by (Responsible Party): Alcon Research Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension. Condition or disease Intervention/treatment Phase Open-Angle Glaucoma Ocular Hypertension Drug: Brinzolamide 1%/brimonidine 0.2

2015 Clinical Trials

90. Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

to baseline of any ocular hypotensive medication. In order to minimize potential risk to subjects due to IOP elevations during the washout period, investigator may choose to substitute a parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic, alpha-agonist, beta-adrenergic blocking agent, or prostaglandins. However, subjects must have discontinued all ocular hypotensive medication for the minimum washout period. Baseline (Day 0/hour 0) IOP ≥ 22 mm Hg and ≤ 34 mm Hg in each eye (...) and Collaborators Actavis Inc. More Information Go to Layout table for additonal information Responsible Party: Actavis Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: WAT/BNZL/2014 First Posted: July 30, 2015 Last Update Posted: February 2, 2017 Last Verified: February 2017 Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Glaucoma Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Brinzolamide Carbonic Anhydrase Inhibitors Enzyme

2015 Clinical Trials

91. Stop Retinal Ganglion Cell Dysfunction Study

Hypertension Eye Diseases Timolol Latanoprost Bimatoprost Travoprost Dorzolamide Acetazolamide Brinzolamide Methazolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Anticonvulsants Carbonic Anhydrase Inhibitors Enzyme Inhibitors Diuretics Natriuretic Agents (...) have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%. Drugs could be: Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation. If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure. Drug: Latanoprost

2015 Clinical Trials

92. PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial

of infectious uveitis, or of scleritis, keratitis, or infectious endophthalmitis in either eye; History of central serous retinopathy in either eye; For women of childbearing potential: pregnancy, breastfeeding, or a positive pregnancy test; unwilling to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for duration of trial; Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline; Oral prednisone dose > 10 mg per day (...) , regardless of the presence of cysts, as assessed by study ophthalmologist; Best corrected visual acuity (BCVA) 5/200 or better; Baseline intraocular pressure > 5 mm Hg and ≤ 21 mm Hg (current use of 3 or fewer intraocular pressure-lowering medications and/or prior glaucoma surgery are acceptable); Baseline fluorescein angiogram that is gradable for leakage in the central subfield Pupillary dilation sufficient to allow OCT testing. Exclusion Criteria: Patient level exclusion criteria: -History

2015 Clinical Trials

93. Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

such as retinal degeneration, diabetic retinopathy, or retinal detachment; Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to approximately 0.60 logMAR, 20/80 Snellen, or 0.25 decimal); Other ocular pathology (including severe dry eye) that may preclude the administration of α-adrenergic agonist and/or topical carbonic anhydrase inhibitor (CAI); Intraocular surgery within the past 6 months; Ocular laser surgery within the past 3 months; Any abnormality preventing reliable (...) Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors

2015 Clinical Trials

94. Glaucoma in pregnancy. (PubMed)

on animal studies. Other glaucoma medications (beta blockers, carbonic anhydrase inhibitors, parasympathomimetics, and prostaglandin analogues) are classified as category C medications with uncertain safety from the lack of human studies and reported adverse effects in animal studies.The treatment of glaucoma during pregnancy and lactation requires careful consideration and understanding of disease status, stage of pregnancy, FDA classification and guidelines, and potential benefits and limitations (...) , the natural course of intraocular pressure during pregnancy, and a discussion of various therapeutic modalities during pregnancy and lactation.The risks of glaucoma medications during pregnancy are not well established for the human fetus or infant and are often inferred from animal studies. Some guidelines have been provided by the US Food and Drug Administration (FDA) about medication safety during pregnancy. Currently, brimonidine is classified as a category B medication with presumed safety based

2014 Current Opinion in Ophthalmology

95. The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness. (PubMed)

).We recommend regular measurements before and during therapy with prostaglandin monotherapy and a combined therapy with prostaglandins, carbonic anhydrase inhibitors, and β-blockers. Follow-up intraocular pressure measurements may be underestimated for eyes treated with the aforementioned treatment regimens if central corneal thickness is not measured on a regular basis. (...) The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness. To evaluate rates of changes per year of central corneal thickness after antiglaucomatous drug administration with β-blockers, prostaglandin analogs, and carbonic anhydrase inhibitors monotherapy and combined topical antiglaucomatous therapy, in a cohort of patients with ocular hypertension, glaucoma suspects, and patients with perimetric glaucoma as compared with normal controls.This retrospective single

2014 Journal of Glaucoma

96. Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa

(diaphragm, condom) with spermicide, or surgical sterilization (hysterectomy or tubal ligation). EXCLUSION CRITERIA: A participant is not eligible if any of the following exclusion criteria are present. Participant is actively receiving study therapy in another investigational study. Participant is started on (or changed dosage of) topical or systemic carbonic anhydrase inhibitor (CAI) treatment in the 3 months prior to enrollment. Participant is actively receiving systemic steroids or has received (...) variability of the CME as well as to measure the variability of the functional testing. Safety outcomes will include the number and severity of adverse events (AEs). Ocular safety outcomes will be indicated by changes in visual acuity, ocular surface changes, intraocular inflammation and any other ocular changes not consistent with the natural progression of RP. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 7 participants

2014 Clinical Trials

97. 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

or topical carbonic anhydrase inhibitor; Intraocular surgery within the past 6 months prior to the Screening Visit; Ocular laser surgery within the past 3 months prior to the Screening Visit; Any abnormality preventing reliable applanation tonometry; Any other conditions including severe illness which would make the subject, in the opinion of the Investigator, unsuitable for the study; History of hepatic or renal disease that would preclude the safe administration of a carbonic anhydrase inhibitor (CAI (...) First Posted: December 29, 2015 Last Update Posted: December 29, 2015 Last Verified: November 2015 Keywords provided by Alcon Research: Glaucoma Ocular Hypertension OAG POAG OHT Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Glaucoma Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Pharmaceutical Solutions Ophthalmic Solutions Travoprost Brinzolamide Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors

2014 Clinical Trials

98. Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration

in the study eye, uncontrolled IOP, or use of two or more agents to control IOP (acetazolamide, beta blocker, alpha-1-agonist, antprostaglandins, carbonic anhydrase inhibitors). Cataract of sufficient severity likely to necessitate surgical extraction within 1 year. History of retinal detachment repair in the study eye. History of malignancy (with the exception of successfully treated [excised] basal cell carcinoma [skin cancer] or successfully treated squamous cell carcinoma of the skin). History (...) -retinal barrier. Glaucoma. Uveitis or other intraocular inflammatory disease. Significant lens opacities or other media opacity. Ocular lens removal within previous 3 months. Ocular surgery in the study eye in the previous 3 months If female, pregnancy or lactation. Any other medical condition, which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromises patient safety, or interferes with the interpretation of the study results. Contacts

2014 Clinical Trials

99. Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

and testing of the retina. The study eye has undergone intraocular surgery within six months prior to enrollment. The study eye is receiving topical carbonic anhydrase inhibitor, or has received topical carbonic anhydrase inhibitors in the past three months. STUDY EYE SELECTION CRITERIA: If both eyes of a participant meet the study eye eligibility criteria, the choice of study eye will be determined as follows: The eye with the worse visual acuity will be selected as the study eye. If both eyes have (...) is currently taking, or has taken in the last three months, a systemic carbonic anhydrase inhibitor prior to enrollment/baseline 1 testing. Participant has any condition that significantly increases risk of systemic corticosteroids or systemic steroid-sparing immuno-modulatory agents, such as HIV, syphilis, tuberculosis, hepatitis B, hepatitis C, or diabetes mellitus (DM). Participant has an underlying serious illness that impairs regular follow-up during the study. Participant has had diagnosis

2014 Clinical Trials

100. Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients

Exclusion Criteria: history of ocular trauma intraocular surgery (except for cataract surgery) eye disease associated with hemodynamic disturbances (except glaucoma) systemic diseases with ocular involvement like diabetes contra-indications to the use of topical beta-blockers or carbonic anhydrase inhibitors Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information (...) as to why these RI values are associated with progression, the clinical question arises as to whether these cutpoints can be modulated by topical glaucoma therapy. As some medications such as carbonic anhydrase inhibitors have been found to have a positive effect in disease progression in what appears to be a non-IOP related effect, we considered the hypothesis that these drugs could have a positive impact on the ocular's microcirculation vasoactive response, potentially enabling to keep a steady MFV

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>